Public Health and Economic Impact of RSVpreF Maternal Vaccination Among Infants in Five Asian Countries
Author(s)
Rengina Kefalogianni, MSc1, Karan Thakkar, MD2, Amy Law, MS, PharmD3, Diana Mendes, PhD1.
1Pfizer Ltd., Tadworth, United Kingdom, 2Pfizer, Singapore, Singapore, 3Pfizer, New York, NY, USA.
1Pfizer Ltd., Tadworth, United Kingdom, 2Pfizer, Singapore, Singapore, 3Pfizer, New York, NY, USA.
OBJECTIVES: Respiratory syncytial virus (RSV) is a common cause of lower respiratory tract infections in infants across Asia. Understanding its public health and economic burden is essential for informing vaccination strategies and increasing disease awareness. This study evaluates the clinical and economic burden of RSV among infants in five Asian countries— Hong Kong, Malaysia, Philippines Singapore and Taiwan —and explores the potential impact of RSVpreF maternal vaccination.
METHODS: The study employed a hypothetical cohort framework and a Markov model to project costs and effects among infants over their first year of life. Outcomes included RSV-related hospitalisations, outpatient visits, deaths, and associated direct medical costs as well as indirect (productivity related) costs. Model inputs were derived from publicly available country-specific epidemiological and cost data, wherever possible. Vaccine effectiveness was based on MATISSE Phase 3 clinical trial results, assuming country-specific uptake rates of existing maternal vaccination programmes ranging from 20%-80%.
RESULTS: Without intervention, 1,465,372 medically-attended RSV cases among infants was projected annually across five countries — including 191,792 hospitalisations and 1,273,580 outpatient visits. Additionally, 4,309 RSV-related deaths were expected each year. The estimated total annual cost attributable to RSV was US$601.75 million (US$485.57 million in direct medical costs and US$116.18 million in indirect costs). With maternal RSVpreF vaccination, approximately 262,446 medically attended infant cases could be prevented annually — including 46,047 hospitalisations, 216,399 outpatient visits, and 1,120 deaths. This would result in cost savings of US$103.64 million and US$27.1 million in direct and indirect costs, respectively.
CONCLUSIONS: RSV places substantial health and economic burden on infants in Asia. The introduction of RSVpreF vaccination could help reduce this burden, preventing medically-attended cases, deaths, and associated costs.
METHODS: The study employed a hypothetical cohort framework and a Markov model to project costs and effects among infants over their first year of life. Outcomes included RSV-related hospitalisations, outpatient visits, deaths, and associated direct medical costs as well as indirect (productivity related) costs. Model inputs were derived from publicly available country-specific epidemiological and cost data, wherever possible. Vaccine effectiveness was based on MATISSE Phase 3 clinical trial results, assuming country-specific uptake rates of existing maternal vaccination programmes ranging from 20%-80%.
RESULTS: Without intervention, 1,465,372 medically-attended RSV cases among infants was projected annually across five countries — including 191,792 hospitalisations and 1,273,580 outpatient visits. Additionally, 4,309 RSV-related deaths were expected each year. The estimated total annual cost attributable to RSV was US$601.75 million (US$485.57 million in direct medical costs and US$116.18 million in indirect costs). With maternal RSVpreF vaccination, approximately 262,446 medically attended infant cases could be prevented annually — including 46,047 hospitalisations, 216,399 outpatient visits, and 1,120 deaths. This would result in cost savings of US$103.64 million and US$27.1 million in direct and indirect costs, respectively.
CONCLUSIONS: RSV places substantial health and economic burden on infants in Asia. The introduction of RSVpreF vaccination could help reduce this burden, preventing medically-attended cases, deaths, and associated costs.
Conference/Value in Health Info
2025-11, ISPOR Europe 2025, Glasgow, Scotland
Value in Health, Volume 28, Issue S2
Code
EPH196
Topic
Epidemiology & Public Health
Topic Subcategory
Public Health
Disease
Respiratory-Related Disorders (Allergy, Asthma, Smoking, Other Respiratory), Vaccines